Gormley Mirinda Ann, Zhang Wanfang, Self Stella, Ewing Joseph A, Heo Moonseong, Roth Prerana, Pericot-Valverde Irene, Rennert Lior, Akiyama Matthew J, Norton Brianna L, Litwin Alain H
Prisma Health Department of Emergency Medicine, 701 Grove Rd. Greenville SC, 29605 USA.
University of South Carolina School of Medicine Greenville, Department of Medicine, 701 Grove road Greenville SC, 29605 USA.
J Subst Use. 2024;29(5):836-842. doi: 10.1080/14659891.2023.2254391. Epub 2023 Sep 6.
Treating hepatitis C virus (HCV) in people who inject drugs (PWID) has been associated with increased health-related quality of life (HRQOL). Polysubstance use (PSU) is common among PWID, but no studies have investigated PSU influence on PWID's HRQOL HCV treatment.
Participants included 150 PWID receiving HCV treatment at opioid agonist treatment clinics in Bronx, NY. The EQ-5D-3L measurement tool assessed five health dimensions producing an index of HRQOL measured at baseline, 4-, 8-, and 12-weeks during treatment and 12- and 24-weeks post-treatment. PSU was determined at baseline. Generalized estimating equations assessed the influence of baseline PSU on changes in mean EQ-5D-3L index over time.
Of the 150 participants, 46 (30.7%) reported PSU and mean HRQOL overall was 0.655, indicating moderate HRQOL. Mean HRQOL was lower at all time-points for the PSU group compared to the non-PSU group. Though PSU group showed improvements in mean HRQOL from baseline (0.614) to 4-, 12- and follow-up week 24 (0.765, 0.768, and 0.731, respectively), the mean change of HRQOL scores was not significantly associated with PSU (p-value=0.956).
For individuals with PWID, our study showed no difference in HRQOL between those who did and did not engage in PSU following HCV treatment.
在注射吸毒者（PWID）中治疗丙型肝炎病毒（HCV）与健康相关生活质量（HRQOL）的提高有关。多物质使用（PSU）在PWID中很常见，但尚无研究调查PSU对PWID接受HCV治疗时HRQOL的影响。
参与者包括在纽约市布朗克斯区阿片类激动剂治疗诊所接受HCV治疗的150名PWID。EQ-5D-3L测量工具评估了五个健康维度，得出在治疗期间基线、4周、8周和12周以及治疗后12周和24周测量的HRQOL指数。PSU在基线时确定。广义估计方程评估了基线PSU对平均EQ-5D-3L指数随时间变化的影响。
在150名参与者中，46名（30.7%）报告有PSU，总体平均HRQOL为0.655，表明HRQOL为中度。与非PSU组相比，PSU组在所有时间点的平均HRQOL都较低。尽管PSU组的平均HRQOL从基线（0.614）到4周、12周和随访第24周（分别为0.765、0.768和0.731）有所改善，但HRQOL评分的平均变化与PSU无显著关联（p值=0.956）。
对于PWID个体，我们的研究表明，HCV治疗后有和没有PSU的个体在HRQOL方面没有差异。
